Are you challenged by the antigenic complexity of the Dengue virus or the urgent need for type-specific therapeutics against DENV4? Creative Biolabs' DENV4 Specific Neutra™ Antibody Products empower your research with high-specificity, rigorously validated antibodies generated through advanced B-cell cloning and epitope-focused engineering, accelerating the development of precise diagnostics and effective countermeasures.
Dengue virus 4 (DENV4) represents one of the four serologically distinct lineages of the Flavivirus genus that pose a significant global public health burden. As an enveloped, positive-sense single-stranded RNA virus, its pathogenicity is dictated by a compact genome encoding three structural and seven non-structural proteins. Central to its infectivity and the host immune response is the Dengue virus 4 Envelope (DENV4-E) protein, which serves as the primary determinant for viral entry and the principal target for neutralizing antibodies.
The DENV4 virion exhibits a sophisticated icosahedral symmetry. The DENV4-E protein is organized into three distinct structural domains (EDI, EDII, and EDIII) and exists primarily as head-to-tail homodimers on the surface of the mature particle. These dimers undergo a low-pH-induced conformational transition into trimeric forms within the endosome to facilitate membrane fusion. The structural integrity of DENV4-E is paramount for receptor-mediated endocytosis, making its surface-exposed epitopes critical for viral neutralization.
DENV4 infection initiates a complex cellular dialogue, primarily sensed by the pattern recognition receptors RIG-I and MDA5. This recognition triggers a robust type I interferon (IFN) response aimed at restricting viral replication. Concurrently, the massive production of viral proteins within the lumen of the endoplasmic reticulum (ER) induces significant ER stress, subsequently activating the Unfolded Protein Response (UPR). The virus has evolved various mechanisms to antagonize these pathways, balancing host cell survival with efficient viral progeny production.
Fig.1 Toll-like receptor activation in response to DENV infection.1
The clinical spectrum of DENV4 infection is broad, ranging from asymptomatic seroconversion to debilitating Dengue Fever (DF). However, the most severe manifestations-Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS)-are characterized by plasma leakage, severe hemorrhage, and organ impairment. These life-threatening conditions are frequently exacerbated by heterologous secondary infections through a mechanism known as Antibody-Dependent Enhancement (ADE).
Fig.2 Model of pathogenesis and antibody-mediated enhancement of dengue virus.2
Neutralizing antibodies are the gold-standard correlate of protection for dengue vaccines. Our DENV4-specific Neutra™ antibodies are essential tools for quantifying type-specific neutralizing titers in vaccine sera using plaque reduction neutralization tests (PRNT) or high-throughput cell-based assays. This allows researchers to precisely evaluate vaccine-induced immunity, dissect the balance between protective and potentially enhancing antibody responses, and ensure vaccine candidates elicit robust, serotype-specific protection against DENV4.
Monoclonal antibodies (mAbs) derived from or characterized using our specific reagents represent promising therapeutic candidates against DENV4. These antibodies can be employed in in vitro and in vivo models to demonstrate direct viral neutralization, block attachment to host cells, and assess protection against challenge. Furthermore, they are critical for studying neutralization kinetics, mapping escape mutations, and understanding the structural basis of epitope recognition to guide the engineering of next-generation, broad-spectrum or pan-serotype therapeutics with minimal ADE risk.
High-specificity anti-DENV4 antibodies enable the development of sensitive immunoassays, such as antigen-capture ELISA or lateral flow tests, for the early detection of DENV4 NS1 antigen in patient samples. Similarly, they are pivotal for serological assays that distinguish DENV4 infections from other flavivirus or heterologous dengue serotype infections. This is vital for accurate epidemiological surveillance, outbreak management, and patient diagnosis in endemic regions.
Creative Biolabs delivers premium antibody solutions designed for the most demanding dengue research:
With over two decades of expertise in virology and antibody development, Creative Biolabs is your dedicated partner in confronting complex infectious diseases like dengue. Our DENV4 Specific Neutra™ Antibody Products are more than just reagents; they are enabling components for discovery, designed to deliver precise, reliable data that accelerates your path from basic research to clinical application. Contact our scientific team today to discuss how our specific Neutra™ antibodies can be integrated into your workflow. We are here to provide detailed product specifications, application support, and custom solution strategies.
References
Recombinant Anti-DENV4 Antibody (V3S-0522-YC7662) (CAT#: V3S-0522-YC7662)
Target: DENV4
Host Species: Mouse
Target Species: Dengue Virus (DENV),
Application: WB,ELISA,FuncS,
Recombinant Chimpanzee Anti-DENV4 Antibody (V3S-0522-YC7663) (CAT#: V3S-0522-YC7663)
Target: DENV4
Host Species: Chimpanzee
Target Species: Dengue Virus (DENV),
Application: WB,ELISA,FuncS,